In my view this happened because IBX was unable to achieve...

In my view this happened because IBX was unable to achieve sufficient detection sensitivity for a high specificity imaging idea, complicates testing for wiggling time, then abandons its core objective (MRX) to re-orientate the tech as an uncompetitive negative contrast agent in MRI. Then without access to new equity borrows monies (now known to have a share price hurdle for additional credit), consolidates shares while maintaining a flawed development path that discourages new equity which then limits new credit.

Opinion only not advice.

Good luck all.